Aliskiren: A Novel, Orally Active Renin Inhibitor

Mohamed Saleem, TS and Jain, A and Tarani, P and Ravi, V and Gauthaman, K (2010) Aliskiren: A Novel, Orally Active Renin Inhibitor. SYSTEMATIC REVIEWS IN PHARMACY,, 1 (1). pp. 93-98. ISSN 0976-2779

Aliskiren[1] K.Gauthaman.pdf

Download (338kB) | Preview
Official URL:


Renin-angiotensin-aldosterone systems play a major role in the regulation of human homeostasis mechanism, which are also involved in the development of hypertension and end-organ damage through activation of angiotensin II. Inhibitors of the renin-angiotensin-aldosterone system may reduce the development of end-organ damage to a greater extent than other antihypertensive agents. Aliskiren is the first member of the new class of orally active direct renin inhibitors recently approved by the US Food and Drug Administration for the treatment of hypertension. Aliskiren directly inhibiting the renin and reducing the formation of angiotensin II, which is the most effective mediator involved in the pathogenesis of cardiovascular diseases. The present review mainly focuses on the pharmacodynamics and pharmacokinetics and clinical aspects of aliskiren. In this respect, the review will improve the basic idea to understand the pharmacology of aliskiren, which is useful for the further research in cardiovascular disease.

Item Type: Article
Subjects: Medicine and Surgery
Pharmaceutical Sciences
Divisions: College of Pharmacy > Pharmacy
Depositing User: GAUTHAMAN Karunakaran
Date Deposited: 11 Mar 2017 12:54
Last Modified: 11 Mar 2017 12:54

Actions (login required)

View Item View Item